Navigation Links
Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
Date:1/15/2009

ults of this pilot study, we anticipate that hGH-CTP could potentially achieve weekly or bi-monthly dosing frequency in humans."

Dr. Havron added, "We look forward to completing these toxicology studies and finalizing the IND for hGH-CTP in the coming months. We are pleased too that our current cash resources should enable us to complete the hGH-CTP Phase I clinical program and continue into Phase II trials over the next 24 months."

ABOUT hGH-CTP (MOD-4023)

hGH-CTP, also known as MOD-4023, is Modigene's proprietary long-acting version of human growth hormone. hGH is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone. Patients using hGH must currently inject the drug between two and seven times each week, a frequency that can be particularly burdensome for pediatric patients. In contrast, hGH-CTP is expected to require only weekly or bi-monthly injections. The primary indications for hGH in children are growth hormone deficiency, kidney disease, Prader-Willi Syndrome and Turner Syndrome. In adults, the primary indications are replacement of endogenous growth hormone and the treatment of AIDS-induced weight loss. In 2007 the annual market for hGH was estimated at $2.5 billion. In addition to its use for medical indications, hGH has been shown to promote a number of "lifestyle" benefits including reversal of non-voluntary weight loss, increased energy levels, enhanced sexual performance, lower cholesterol and improved appearance of the skin.

ABOUT CTP

Modigene's CTP technology was discovered by researchers at Washington University in St. Louis and is based on a short amino acid sequence that occurs naturally in humans, the carboxyl terminal peptide (CTP). When attached to a therapeutic protein, CTP extends the time that the protein is active in the body. The potential utility of the tec
'/>"/>

SOURCE Modigene Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
2. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
3. Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
(Date:10/22/2014)... CITY, Calif., Oct. 21, 2014 Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today reported financial results ... Second quarter overview: , Revenues of ... , Diluted EPS of $0.24, up 33% over ... , Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... an August 2014 report by Global Research & Data ... 6.2% per year from 2014 through 2018, as demand ... United States is the world,s largest market ... market with advanced thermometers is Sanomedics International Holdings, Inc. ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2
... California, 23 May 2007 - The antidepressant duloxetine,hydrochloride ... patients who did not respond, or responded only,partially, ... regardless of whether those patients were,switched from an ... was presented today at the American Psychiatric,Association’s 160 ...
... - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical company that ... today announced that clinical findings for three,different TAP ... to be,reported at the 43rd American Society of ... 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 (abstract #1042) ...
Cached Medicine Technology:In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 2In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 3In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 4In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 5In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 6In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 7In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 8In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 9ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3
(Date:10/25/2014)... NY (PRWEB) October 26, 2014 BioSkinLaser.Com, ... announces the most advanced and improved laser treatments for ... and safe treatments like the lip enhancement treatment ... keeping with specific focus areas of each customer. , ... cellulite reduction NYC . The company cited that ...
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival ... (Alimta), after his combination drug therapy became too toxic. ... just posted on the Surviving Mesothelioma website. , ... in Japan suggests that “maintenance therapy” with pemetrexed may ... cannot tolerate higher doses of cisplatin. , “Although ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
Breaking Medicine News(10 mins):Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 2Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2
... flies. And it,s not just because they breed like ... and developmental biology by breeding and studying fruit flies (Drosophila ... important research animals because they reproduce quickly and, well, fruitfully; ... many genes and proteins with humans. Now there,s a ...
... study into Staphylococcus aureus , the bacterium which ... bacteria have developed a strategy of hiding within host ... many antibacterial treatments. The research, published by EMBO ... to adapt to their environmental conditions, lie dormant inside ...
... 700,000 for each of the 2011 prizes, of which CHF ... CHF 100,000 for their personal use. The prize ... be of considerable significance for medicine. Stefan Jentsch is ... his work on small protein modifiers and their role in ...
... , WEDNESDAY, Jan. 26 (HealthDay News) -- Screening ... higher in the United States among young black and ... explain why black and Hispanic women have higher reported ... Researchers who analyzed data from more than 40,000 visits ...
... conducted at Sahlgrenska University Hospital in Gothenburg and at ... of 18 and 65. Half the group was randomly ... half to maintain their usual lifestyle. Both groups ... group increased their physical activity on their own, but ...
... , TUESDAY, Jan. 25 (HealthDay News) -- Longevity isn,t increasing ... other developed countries, says a new report that points a ... 25 years, U.S. life expectancy at age 50 has increased, ... countries studied, including Japan and Australia, notes the report from ...
Cached Medicine News:Health News:Zebrafish popular with researchers 2Health News:Research shows how pathogenic bacteria hide inside host cells 2Health News:2011 Louis-Jeantet Prize for Medicine 2Health News:2011 Louis-Jeantet Prize for Medicine 3Health News:2011 Louis-Jeantet Prize for Medicine 4Health News:2011 Louis-Jeantet Prize for Medicine 5Health News:More Screenings May Explain Higher Chlamydia Rates Among Minorities 2Health News:Smoking, Obesity Slowing U.S. Life Expectancy Gains: Report 2Health News:Smoking, Obesity Slowing U.S. Life Expectancy Gains: Report 3
... Featuring an expanded database containing ... new identification cards, VITEK 2 Compact ... minimum amount of time (2 to ... majority of microorganisms that contaminate production ...
... Horizon Cardiology Hemo is a comprehensive ... for the cath lab. Patient ... cardiac images and procedural information all ... patient record, eliminating repetitive data entry. ...
... generation product is a patient monitoring system ... parameters, sensed at the tissue level, reflecting ... tissue by low power light and detects ... tissue. The light is guided to the ...
PowerMed is a billing software....
Medicine Products: